Beth is responsible for driving business development and thought leadership initiatives for the biotechnology / biopharma sector. Beth also advises Lumanity’s clients in corporate and partnering strategies across modalities, therapeutic areas and stages-of-development. In addition to her role at Lumanity, Beth advises IP strategy and negotiates transactions for the Wake Forest Institute for Regenerative Medicine.
In her previous roles in executive management in private and public biotech companies and research institutions over 30 years, Beth drove corporate, pipeline and partnering strategies, led BD, licensing and IP, managed alliances and projects, and developed corporate communications and served as a corporate spokesperson. Beth has a robust deal sheet across therapeutic areas, modalities and stages of development, including cell and gene therapy, CNS, inflammatory disease, etc. Prior to joining Lumanity, Beth founded and led NovoCreation Consulting, LLC, from 2013-2019, advising and negotiating deals for biotech and research institution clients. At Targacept, Inc. from 2003-2010, culminating in the role of VP, Licensing and IP, Beth secured transforming deals with global pharma leading to deal revenues of >$650 million, including a $1.2B co-development, co-promotion deal with AstraZeneca for a single P3-ready compound for depression. That AZ deal was a finalist for Deloitte Recap’s Breakthrough Alliance of the Year in 2010. Additional deals Beth negotiated with AZ and GlaxoSmithKline were awarded the Licensing Executives Society (LES) Life Science Deal of Distinction in 2008.
Beth received her BS from High Point University and is a Certified Licensing Professional® and member of the Licensing Executives Society.